Video

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer

Author(s):

Mansoor Raza Mirza, MD

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Mansoor Raza Mirza, MD, medical director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit and chief oncologist within the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the safety ​profile of niraparib (Zejula) in combination with bevacizumab (Avastin) in platinum-sensitive recurrent ovarian cancer.

During the 2020 ASCO Virtual Scientific Program, final analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trialdemonstrated continued, statistically significant activity with the combination compared with niraparib alone in this patient population.

Notably, no new safety signals were observed with the regimen, says Mirza. Some patients experienced adverse effects such as hypertension and proteinuria, but they were not unexpected in this setting.

Moreover, no deterioration in quality of life according to patient-reported outcomes ​was reported with the combination versus niraparib alone, Mirza concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Aparna Parikh, MD
July 19th 2024

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

FDA
July 3rd 2024

OncLive’s June Roundup of Key FDA Approvals in Oncology

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.
June 28th 2024

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

Susana Banerjee, MBBS, MA, PhD, FRCP, consultant medical oncologist, research lead, Gynaecology Unit, The Royal Marsden NHS Foundation Trust
June 21st 2024

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications